Condition
Lung Cancer (Locally Advanced or Metastatic)
Total Trials
5
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (3)
P 2 (1)
Trial Status
Not Yet Recruiting3
Active Not Recruiting1
Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07457541Phase 1Active Not RecruitingPrimary
Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI
NCT07461662Not ApplicableNot Yet RecruitingPrimary
Evaluation of Endobronchial Ultrasound Needle Cleaning Techniques and Their Impact on Specimen Contamination
NCT07303881Phase 2Not Yet Recruiting
Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
NCT03556228Phase 1Recruiting
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
NCT07260058Phase 1Not Yet RecruitingPrimary
Immune Cell Therapy for Advanced Solid Tumors
Showing all 5 trials